Taylor Frigon Capital Management LLC Cuts Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Taylor Frigon Capital Management LLC decreased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 10.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 27,207 shares of the medical research company’s stock after selling 3,141 shares during the quarter. Taylor Frigon Capital Management LLC’s holdings in Edwards Lifesciences were worth $2,014,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Harbor Capital Advisors Inc. grew its holdings in shares of Edwards Lifesciences by 2.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after buying an additional 273 shares during the last quarter. Nordea Investment Management AB boosted its holdings in Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after purchasing an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its holdings in Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock worth $355,344,000 after purchasing an additional 300,000 shares during the last quarter. Sivik Global Healthcare LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth approximately $3,702,000. Finally, Avanza Fonder AB purchased a new stake in Edwards Lifesciences in the fourth quarter worth approximately $4,845,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now directly owns 60,372 shares of the company’s stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 26,489 shares of company stock worth $2,002,829. Insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Finally, Truist Financial reiterated a “hold” rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $71.96 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market cap of $42.44 billion, a P/E ratio of 10.32, a P/E/G ratio of 4.82 and a beta of 1.11. The firm’s fifty day moving average is $72.76 and its two-hundred day moving average is $70.19. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.